Halozyme Therapeutics (NASDAQ:HALO) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a strong-buy rating to a hold rating in a research report released on Saturday.

Other equities analysts have also recently issued reports about the company. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Finally, TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $78.56.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $70.64 on Friday. The company’s 50-day moving average is $72.29 and its two-hundred day moving average is $70.54. Halozyme Therapeutics has a 1-year low of $47.50 and a 1-year high of $82.22. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 3.66. The firm has a market capitalization of $8.34 billion, a price-to-earnings ratio of 28.37, a PEG ratio of 0.29 and a beta of 0.97.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). The firm had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm’s quarterly revenue was up 51.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.26 EPS. Analysts forecast that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $55,733,662.16. This represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director directly owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This represents a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 49,398 shares of company stock worth $3,650,592. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Root Financial Partners LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $25,000. Larson Financial Group LLC increased its stake in shares of Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the period. Measured Wealth Private Client Group LLC raised its holdings in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares in the last quarter. Richardson Financial Services Inc. raised its holdings in Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 198 shares in the last quarter. Finally, Clearstead Advisors LLC lifted its stake in Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 265 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.